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$977, and cardiovascular illness $35. The incremental
cost of diabetes co-occurring with psychosis was signifi-
cantly higher than all other disease co-occurrences. Dif-
ferences in the incremental cost of diabetes were not sta-
tistically significant between the other disease combinations.
ANCOVA was performed with longevity in the program
as a covariate to adjust for differential enrollment time.
CONCLUSION: The cost and management of chronic
conditions such as diabetes may be highly influenced by
other chronic conditions the patient may have. Disease
management programs may incorporate co-morbidity re-
search and models when evaluating the cost and treat-
ment of chronic conditions.
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OBJECTIVE: To obtain a profile of adult patients at risk
for nonsteroidal anti-inflammatory drug (NSAID) in-
duced gastrointestinal (GI) complications in a large man-
aged care health plan in the Southwest United States.
METHODS: Patients with NSAID prescription claims
between July 1996 and June 1997 were identified from a
health plan claims database. Patients with claims associ-
ated with ICD-9 and CPT codes indicating serious GI
complications were then identified. The ICD-9 codes
used were those associated with GI ulcers (531.x, 532.x,
533.x, and 534). A total of 19 CPT codes for GI proce-
dures indicative of a GI complication were used. A for-
ward stepwise logistic regression analysis, using the likeli-
hood-ratio (LR) test, was performed to identify predictors
of GI complications. Predictors included in the model
were individual NSAIDs and the following potential risk
factors: age, gender, previous GI drug usage, previous
steroid usage, and total days supply of NSAIDs during
the study period. RESULTS: A sample of 15,772 patients
with prescription claims for NSAIDs was identified. Of
these patients, 213 (1.4%) had an ICD-9 or CPT code
suggestive of serious GI complications secondary to a
NSAID. The logistic regression results indicated that
women (OR  0.65, 95% CI  0.48–0.87) were less
likely to develop GI complications. However, patients
with previous GI drug usage (OR  5.97, 95% CI 
4.51–7.90), those who used ketorolac (OR  2.01, 95%
CI  1.10–3.67) and those who used oxaprozin (OR 
1.82, 95% CI  1.10–3.00) were more likely to develop
GI complications. CONCLUSION: Users of ketorolac
and oxaprozin, as well as those with previous GI drug us-
age were at a higher risk, while women were at a lower
risk of GI complications in this managed care population.
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OBJECTIVES: The primary objective was to describe the
cost of illness of gastroesophageal reflux disease (GERD)
in a managed care population. Secondary objectives were
to characterize GERD costs and to quantify the depen-
dence of costs on disease severity. METHODS: This ret-
rospective study utilized claims data from a large (1.4
million lives) Midwest USA health care plan. Study popu-
lation had complete medical and pharmacy coverage con-
tinuously from 1996 to 1998 and possessed at least one
medical claim for GERD. Claim costs were compiled for
all GERD-attributable medical and drug claims. Costs
were also categorized by health care sector, such as hos-
pital inpatient or pharmacy. ICD-9 codes were used to
categorize subjects’ GERD into four progressively worse
states plus a non-symptomatic state: GERD0 {no GERD
claims}, GERD1 {mild esophagitis}, GERD2 {reflux esoph-
agitis}, GERD3 {esophageal ulceration}, and GERD4 {stric-
tures and complications}. RESULTS: A total of 7575 sub-
jects meeting the inclusion and exclusion criteria were
identified. The median age was 50 and there were 50%
females. Over the three year study period, more than $23
million was spent on GERD-related claims, or $86 per
subject per month. Pharmacotherapy contributed 31% of
GERD health care costs, inpatient hospital charges 37%,
outpatient facility charges 26%, and doctor office charges
6%. Mean cost per month was highly dependent on GERD
disease state: GERD0 cost $38 per month, GERD1 was
$189, GERD2 was $232, GERD3 was $536, and GERD4
was $412. At higher GERD states, pharmacotherapy was
a lower contributor to cost. CONCLUSIONS: For payers
of health care, GERD is an expensive disorder to manage.
Overall costs associated with GERD increase with the se-
verity of the disease, although the relative contribution of
each health care cost sector changes with disease severity.
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OBJECTIVE: To model the relationship between resis-
tance to trimethoprim sulphamethoxazole (TMP-SXT)
